Ligand ID: VLB


Drugbank ID:
DB00570
(Vinblastine)


Indication:
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Get human targets for VLB in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'VLB' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
LYS A 102
ASP A 176
TYR A  37
LEU A  32
1.74A20.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		5r82 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.26A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 108
ILE A 249
VAL A 202
ILE A 200
1.53A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.29A18.61
15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.73A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 297
THR A 292
PRO A 293
LEU A 253
1.66A16.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
VAL A 202
ILE A 249
PHE A 294
ILE A 200
1.57A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
LYS A1191
VAL A1189
ASN A1192
GLY B 932
ILE B 934
1.38A16.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.76A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.49A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.73A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.30A20.25
21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.66A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS B 378
VAL B 433
THR B 430
LEU B 425
1.28A17.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.76A21.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.75A21.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.30A20.82
21.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.50A21.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.67A21.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO D 293
VAL D 202
PHE D 230
ILE D 249
1.50A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PRO B 132
ILE B 136
ALA B 173
GLY B 109
ILE B 200
1.78A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.57A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU D 250
PRO D 293
ASN D 203
ALA D 129
ILE D 249
1.77A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.62A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL C 204
PRO C 293
ILE C 259
VAL C 212
ILE C 213
1.36A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE B 259
ALA B 260
VAL B 212
GLY B 215
ILE B 213
1.64A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
LYS B 102
THR B 175
TYR B  37
LEU B  30
1.52A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO C 293
VAL C 202
PHE C 230
ILE C 249
1.48A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.70A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU C 250
PRO C 293
ASN C 203
ALA C 129
ILE C 249
1.74A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO B 293
VAL B 202
PHE B 230
ILE B 249
1.57A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL B 204
PRO B 293
ILE B 259
VAL B 212
ILE B 213
1.32A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.78A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE D 259
ALA D 260
VAL D 212
GLY D 215
ILE D 213
1.69A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PRO D 132
ILE D 136
ALA D 173
GLY D 109
ILE D 200
1.74A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU B 250
PRO B 293
ASN B 203
ALA B 129
ILE B 249
1.70A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.33A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL C  77
ASP C  92
THR C  21
LEU C  87
1.35A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL D 204
PRO D 293
ILE D 259
VAL D 212
ILE D 213
1.38A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.54A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.66A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.28A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 108
ILE A 249
VAL A 202
ILE A 200
1.54A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 202
ILE A 249
PHE A 294
ILE A 200
1.52A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.78A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A  32
LYS A 102
VAL A 157
ILE A 152
VAL A  13
1.79A20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
LYS A 478
VAL A 475
TYR A 746
LEU A 749
1.42A18.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 7
ASN A 703
PHE A 766
VAL A 764
ILE A 757
1.17A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 164
TYR A 156
TYR A 175
LEU A 146
1.61A18.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A 700
ILE A 696
PHE A 480
VAL A 475
1.30A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 284
PRO A 232
TYR A 238
LEU A 205
1.36A18.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 184
ILE A 450
ALA A 448
VAL B 131
ILE B 185
1.46A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ASN A 703
ALA A 706
PHE A 766
VAL A 764
ILE A 757
1.54A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.43A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
LYS A 188
THR A 206
TYR A 238
LEU A 241
1.09A18.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 5
VAL A 398
ASN B 118
VAL A 675
ILE A 539
1.70A20.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PRO B 121
ILE B 107
VAL B 115
ILE B 119
1.48A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A  42
ASN A  39
ILE A  37
PHE A  35
1.53A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LYS A 391
VAL B 131
ILE B 185
VAL A 405
GLY A 671
1.53A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		4 / 6
ASP A 284
PRO A 232
TYR A 238
LEU A 205
1.44A18.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LEU B 184
ILE A 450
ALA A 449
VAL B 131
ILE B 185
1.47A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL B 131
ILE B 185
VAL A 405
ILE A 450
1.28A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 576
VAL A 587
ILE A 757
ALA A 762
ILE A 579
1.58A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ASP A 389
TYR A 369
TYR A 365
LEU A 368
1.62A15.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
VAL B  36
TYR B  38
THR B 286
LEU B 277
1.41A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PRO A  51
VAL A  52
ASN A  53
ILE A  27
1.10A20.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL B 151
TYR B 152
THR B  13
LEU B 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL A 155
ASP A  22
TYR A 161
LEU A 164
1.52A
SO4  A 203 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL B 155
ASP B  22
TYR B 161
LEU B 164
1.41A
SO4  B 204 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 6
ASP B  66
PRO A  74
TYR A  68
LEU A  43
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.26A
None
None
SO4  B 204 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.33A
None
None
SO4  A 203 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASP B  66
PRO A  74
TYR A  68
LEU A  43
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
VAL B  16
ASP B  14
TYR B 152
LEU B 153
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vxs NSP3
(SARS-CoV-2)		4 / 8
LYS A  29
THR A  33
PRO A  32
LEU A  88
1.53A
None
NHE  A 202 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
PRO A 330
ASN A 544
VAL A 524
ILE A 332
1.48A15.80
NAG  A1306 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PRO C 521
ASN C 544
PHE C 541
VAL C 576
1.17A15.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_1
(TUBULIN BETA-2B
CHAIN
TUBULIN ALPHA-1B
CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LYS A 378
VAL A 433
TYR A 380
THR A 430
LEU A 425
1.62A15.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS A 378
VAL A 433
THR A 430
LEU A 425
1.26A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 5
PRO C 337
ASN C 334
VAL C 524
ILE C 358
1.79A16.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 510
ILE C 434
PHE C 377
ILE C 402
1.73A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 433
ILE C 434
PHE C 374
VAL C 510
1.74A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 433
PHE C 342
VAL C 510
ILE C 410
1.59A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
THR H  31
PRO C 384
TYR C 365
LEU C 387
1.80A16.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 433
ILE C 434
PHE C 342
VAL C 510
1.52A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
ILE C 434
PHE C 342
VAL C 510
ILE C 402
1.67A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 510
ILE C 434
PHE C 374
ILE C 402
1.54A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_1
(TUBULIN BETA-2B
CHAIN
TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 9
LYS C 378
VAL C 433
TYR C 380
THR C 430
LEU C 425
1.61A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP C 389
THR H 100
PRO H 100
LEU L  46
1.26A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 395
ASN C 394
ILE C 358
VAL C 524
1.49A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 512
ILE C 434
PHE C 374
VAL C 510
1.62A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP C 389
THR H  31
TYR C 365
LEU C 368
1.74A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
THR C 470
PRO C 491
TYR C 421
LEU C 455
1.72A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 8
LYS C 378
VAL C 433
TYR C 380
THR C 430
LEU C 425
1.63A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
PRO C 337
ASN C 334
VAL C 524
ILE C 358
1.68A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
VAL C 510
PHE C 377
VAL C 433
ILE C 410
1.77A15.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
VAL A6865
ASP A6895
THR A6889
PRO A6888
1.80A16.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w61 NSP10
(SARS-CoV-2)		4 / 7
ILE B4352
PHE B4321
VAL B4350
ILE B4308
1.75A17.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A6965
ILE A6925
PHE A6868
ILE A7005
1.63A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
VAL A6859
THR A6889
PRO A6888
LEU A7050
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ILE A6866
PHE A6954
VAL A6916
ILE A6910
1.59A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.33A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.59A15.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.66A15.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL A 155
ASP A  22
TYR A 161
LEU A 164
1.52A
AMP  A 201 ( 4.4A)
AMP  A 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL B 155
ASP B  22
TYR B 161
LEU B 164
1.56A19.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL B 151
TYR B 152
THR B  13
LEU B 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.27A
None
None
AMP  A 201 ( 4.4A)
AMP  A 201 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL B  16
ASP B  14
TYR B 152
LEU B 153
1.54A19.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 5
VAL C7094
ASN C7095
VAL A7086
ILE A7088
1.66A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP10
(SARS-CoV-2)		4 / 7
ILE B4352
PHE B4321
VAL B4350
ILE B4308
1.78A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C7094
ASN C7095
VAL A7086
ILE A7088
1.55A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6w75 NSP10
(SARS-CoV-2)		4 / 6
LYS B4271
ASP B4275
TYR D4283
LEU D4328
1.75A14.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A7094
ASN A7095
VAL C7086
ILE C7088
1.59A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
VAL A6859
THR A6889
PRO A6888
LEU A7050
1.54A16.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ILE A6951
PHE A6954
VAL A6965
ILE A7005
1.64A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
VAL C6859
THR C6889
PRO C6888
LEU C7050
1.52A16.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C6965
ILE C6925
PHE C6868
ILE C7005
1.64A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ILE C6866
PHE C6954
VAL C6916
ILE C6910
1.60A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A6965
ILE A6925
PHE A6868
ILE A7005
1.64A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		5 / 12
LYS C6968
PHE C6954
VAL C6965
GLY C7006
ILE C7005
1.67A16.37
FMT  C7108 ( 3.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 5
VAL A7094
ASN A7095
VAL C7086
ILE C7088
1.71A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP10
(SARS-CoV-2)		4 / 7
ILE D4352
PHE D4321
VAL D4350
ILE D4308
1.78A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
VAL A6865
ASP A6895
THR A6889
PRO A6888
1.79A16.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ILE A6866
PHE A6954
VAL A6916
ILE A6910
1.59A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
PRO C  46
VAL C  21
VAL C   7
ILE C   5
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 6
ASP A  76
TYR A 171
TYR A 154
LEU A 172
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
ASP B 286
THR B 301
TYR B 296
LEU B 253
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
PRO B  46
VAL B  21
VAL B   7
ILE B   5
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
ASP A 286
THR A 301
TYR A 296
LEU A 253
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
ASP C 286
THR C 301
TYR C 296
LEU C 253
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_1
(TUBULIN BETA-2B
CHAIN
TUBULIN ALPHA-1B
CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 9
ASP B 286
PHE B 304
THR B 301
TYR B 296
LEU B 253
1.37A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 5
PRO A  46
VAL A  21
VAL A   7
ILE A   5
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 6
ASP B  76
TYR B 171
TYR B 154
LEU B 172
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wcf NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wcf NSP3
(SARS-CoV-2)		4 / 8
LYS A  29
THR A  33
PRO A  32
LEU A  88
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wcf NSP3
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wcf NSP3
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wcf NSP3
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wcf NSP3
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wen NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wen NSP3
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wen NSP3
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wen NSP3
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wen NSP3
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wen NSP3
(SARS-CoV-2)		4 / 7
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wey NSP3
(SARS-CoV-2)		5 / 12
LEU A 313
PRO A 302
VAL A 304
ASN A 303
ILE A 310
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wey NSP3
(SARS-CoV-2)		4 / 7
PRO A 329
ILE A 222
VAL A 359
ILE A 227
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wey NSP3
(SARS-CoV-2)		4 / 8
VAL A 355
TYR A 356
THR A 217
LEU A 357
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wey NSP3
(SARS-CoV-2)		4 / 5
PRO A 302
VAL A 304
ASN A 303
ILE A 310
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU A 331
LYS B 355
ASN B 354
GLY A 321
ILE A 320
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU C 331
LYS D 355
ASN D 354
GLY C 321
ILE C 320
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU F 331
LYS E 355
ASN E 354
GLY F 321
ILE F 320
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
VAL C6859
THR C6889
PRO C6888
LEU C7050
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
VAL C7094
ASN C7095
VAL A7086
ILE A7088
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wjt NSP10
(SARS-CoV-2)		4 / 6
LYS B4271
ASP B4275
TYR D4283
LEU D4328
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
VAL A7094
ASN A7095
VAL C7087
ILE C7088
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
VAL A7094
ASN A7095
VAL C7086
ILE C7088
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LYS C6968
PHE C6954
VAL C6965
GLY C7006
ILE C7005
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
ASP A 144
PRO A 122
TYR A  86
LEU A 121
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wkq NSP10
(SARS-CoV-2)		4 / 6
LYS B4271
ASP B4275
TYR D4283
LEU D4328
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wkq NSP16
(SARS-CoV-2)		5 / 12
LYS C6968
PHE C6954
VAL C6965
GLY C7006
ILE C7005
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wkq NSP16
(SARS-CoV-2)		4 / 5
VAL A7094
ASN A7095
VAL C7087
ILE C7088
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wkq NSP16
(SARS-CoV-2)		4 / 8
VAL C6859
THR C6889
PRO C6888
LEU C7050
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL B 237
ILE B 236
PHE B 342
ILE B 253
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL B  67
ASN B  63
ILE B  86
ILE B 144
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PRO B  51
VAL B  52
ASN B  53
ILE B  27
1.13A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL A  67
ASN A  63
ILE A  86
ILE A 144
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU B 255
VAL B 237
ILE B 236
ALA B 232
PHE B 342
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PRO A  51
VAL A  52
ASN A  53
ILE A  27
1.10A
None
None
EDO  A 403 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU A 255
VAL A 237
ILE A 236
ALA A 232
PHE A 342
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
VAL A 237
ILE A 236
PHE A 342
ILE A 253
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.33A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 108
ILE A 249
VAL A 202
ILE A 200
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
LYS A 102
THR A 175
TYR A  37
LEU A  30
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL D  16
ASP D  14
TYR D 152
LEU D 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.27A
None
None
None
APR  B 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 151
TYR C 152
THR C  13
LEU C 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ASP A  22
TYR A 161
LEU A 164
1.43A
None
APR  A 201 (-4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL B 155
ASP B  22
TYR B 161
LEU B 164
1.45A
None
APR  B 201 (-3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL D 151
TYR D 152
THR D  13
LEU D 153
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.30A
None
None
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LYS A  44
VAL A  41
ASN A  40
VAL A  77
GLY A  79
1.79A
None
None
APR  A 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL D 155
ASP D  22
TYR D 161
LEU D 164
1.41A
None
APR  D 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO D 125
ILE D  18
VAL D 155
ILE D  23
1.31A
None
None
None
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ASP C  22
TYR C 161
LEU C 164
1.46A
None
APR  C 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO C 125
ILE C  18
VAL C 155
ILE C  23
1.30A
None
None
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU C 109
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C  16
ASP C  14
TYR C 152
LEU C 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL B 151
TYR B 152
THR B  13
LEU B 153
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU D 109
PRO D  98
VAL D 100
ASN D  99
ILE D 106
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
VAL A6859
THR A6889
PRO A6888
LEU A7050
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ILE A6866
PHE A6954
VAL A6916
ILE A6910
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqd NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wqd NSP8
(SARS-CoV-2)		4 / 6
LYS D 139
ASP D 112
TYR D 135
LEU D 184
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
LEU C  60
PRO D 116
ALA D 126
VAL C  53
ILE D 106
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wqd NSP8
(SARS-CoV-2)		5 / 12
TYR B 135
THR B 137
ILE B 156
VAL B 159
ILE B 185
1.54A15.08
14.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqd NSP8
(SARS-CoV-2)		4 / 7
PRO D 183
ILE D 172
VAL D 159
ILE D 185
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
LEU A  60
PRO B 116
ALA B 126
VAL A  53
ILE B 106
1.74A
None
None
None
EDO  B 302 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wqd NSP8
(SARS-CoV-2)		5 / 12
TYR D 135
THR D 137
ILE D 156
VAL D 159
ILE D 185
1.53A15.08
14.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wqd NSP8
(SARS-CoV-2)		4 / 6
LYS B 139
ASP B 112
TYR B 135
LEU B 184
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqd NSP8
(SARS-CoV-2)		4 / 7
PRO B 116
VAL B 130
ILE B 185
ILE B 120
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A  30
LYS A 102
VAL A 157
ILE A 152
VAL A  13
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.25A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
VAL A 202
ILE A 249
PHE A 294
ILE A 200
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PRO A 108
ILE A 249
VAL A 202
ILE A 200
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
ASP A 286
THR A 301
TYR A 296
LEU A 253
1.38A
None
GOL  A 508 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_1
(TUBULIN BETA-2B
CHAIN
TUBULIN ALPHA-1B
CHAIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 9
ASP A 286
PHE A 304
THR A 301
TYR A 296
LEU A 253
1.49A21.89
None
None
GOL  A 508 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
PRO A  46
VAL A  21
VAL A   7
ILE A   5
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 5
PRO A  46
VAL A  21
VAL A   7
ILE A   5
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 297
THR A 292
PRO A 293
LEU A 253
1.64A18.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.75A16.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.67A16.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.29A18.61
16.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL A 202
ILE A 249
PHE A 294
ILE A 200
1.62A16.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
TYR D 135
THR D 137
ILE D 156
VAL D 159
ILE D 185
1.58A15.22
16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
ASN B 105
ILE B 106
VAL B 130
ILE B 132
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
PRO B 116
VAL B 130
ILE B 185
ILE B 120
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
LEU C  60
PRO D 116
ALA D 126
VAL C  53
ILE D 106
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
PRO D 183
ILE D 172
VAL D 159
ILE D 185
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
TYR B 135
THR B 137
ILE B 156
VAL B 159
ILE B 185
1.57A15.22
16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A  93
TYR A  47
TYR A  83
ASN A  35
ILE A  34
1.76A14.03
15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 434
PHE A 374
ILE A 402
1.54A
None
None
DMS  A 901 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ASP L  66
TYR B  27
THR B   0
TYR A 369
ILE L  54
1.74A18.81
17.86
None
None
MLI  B 303 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
VAL L  64
ASP L  66
THR A 385
TYR B  27
ASN A 388
1.67A18.81
17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 434
PHE E 374
ILE E 402
1.56A
None
None
DMS  E 901 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 395
ASN E 394
ILE E 358
VAL E 524
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 433
ILE A 434
PHE A 342
VAL A 510
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS A 378
VAL A 433
THR A 430
LEU A 425
1.30A
MLI  B 302 ( 4.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL E 407
ILE E 410
ALA E 419
LYS E 424
VAL E 433
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 433
ILE E 434
PHE E 342
VAL E 510
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP E 389
THR H 104
PRO H 105
LEU L  52
1.13A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS E 378
VAL E 433
THR E 430
LEU E 425
1.34A
MLI  E 908 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
ASP C  66
TYR H  27
THR H   0
TYR E 369
ILE C  54
1.70A18.81
17.86
None
None
MLI  B 303 (-4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP A 389
THR B 104
PRO B 105
LEU C  52
1.04A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP E 389
THR H 104
PRO H 105
LEU L  52
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 512
ILE E 434
PHE E 374
VAL E 510
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 434
PHE E 374
ILE E 402
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS E 378
VAL E 433
THR E 430
LEU E 425
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 433
ILE E 434
PHE E 342
VAL E 510
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 395
ASN E 394
ILE E 358
VAL E 524
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 108
ILE A 249
VAL A 202
ILE A 200
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.34A20.54
21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
LYS A 102
ASP A 176
TYR A  37
LEU A  32
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A 407
ILE A 410
ALA A 419
LYS A 424
VAL A 433
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 510
ILE E 434
PHE E 374
ILE E 402
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP E 389
THR H 104
PRO H 105
LEU L  52
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 433
ILE E 434
PHE E 342
VAL E 510
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS A 378
VAL A 433
THR A 430
LEU A 425
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
LYS E 378
VAL E 433
THR E 430
LEU E 425
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 510
ILE A 434
PHE A 374
ILE A 402
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 395
ASN A 394
ILE A 358
VAL A 524
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ASP A 389
THR B 104
PRO B 105
LEU C  52
1.12A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL E 407
ILE E 410
ALA E 419
LYS E 424
VAL E 433
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL E 395
ASN E 394
ILE E 358
VAL E 524
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
VAL A 433
ILE A 434
PHE A 342
VAL A 510
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.50A
None
PEG  A 405 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.73A
None
None
PEG  A 405 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.75A
None
None
None
PEG  A 405 (-3.3A)
PEG  A 405 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.28A20.54
21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B  16
ASP B  14
TYR B 152
LEU B 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C 109
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.59A
None
None
EDO  C 208 ( 4.7A)
None
EDO  C 208 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E 155
ASP E  22
TYR E 161
LEU E 164
1.53A
EDO  E 205 ( 4.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D 155
ASP D  22
TYR D 161
LEU D 164
1.52A
EDO  D 208 ( 4.2A)
EDO  D 209 ( 3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO E  98
VAL E 100
ASN E  99
ILE E 106
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E 109
PRO E  98
VAL E 100
ASN E  99
ILE E 106
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.61A
None
EDO  C 208 ( 4.7A)
None
EDO  C 208 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
ILE E  18
VAL E 155
ILE E  23
1.27A
None
None
EDO  E 205 ( 4.2A)
EDO  E 205 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E 151
TYR E 152
THR E  13
LEU E 153
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B 155
ASP B  22
TYR B 161
LEU B 164
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D 151
TYR D 152
THR D  13
LEU D 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E  16
ASP E  14
TYR E 152
LEU E 153
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 151
TYR C 152
THR C  13
LEU C 153
1.49A
None
EDO  C 203 (-4.8A)
EDO  C 205 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A 155
ASP A  22
TYR A 161
LEU A 164
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 155
ASP C  22
TYR C 161
LEU C 164
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
ILE C  18
VAL C 155
ILE C  23
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU D 109
PRO D  98
VAL D 100
ASN D  99
ILE D 106
1.61A
EDO  D 204 ( 4.5A)
None
None
None
EDO  D 204 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO D  98
VAL D 100
ASN D  99
ILE D 106
1.65A
None
None
None
EDO  D 204 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B 151
TYR B 152
THR B  13
LEU B 153
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D  16
ASP D  14
TYR D 152
LEU D 153
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
ILE D  18
VAL D 155
ILE D  23
1.32A
None
None
EDO  D 208 ( 4.2A)
EDO  D 208 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
LYS D  29
THR D  33
PRO D  32
LEU D  88
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.76A
None
None
None
None
EDO  A 204 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C 109
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B 155
ASP B  22
TYR B 161
LEU B 164
1.44A
None
APR  B 201 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU D 109
PRO D  98
VAL D 100
ASN D  99
ILE D 106
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B 101
ILE B 131
VAL E 100
ILE E 106
1.51A
None
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E 151
TYR E 152
THR E  13
LEU E 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B 151
TYR B 152
THR B  13
LEU B 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LYS E  44
VAL E  41
ASN E  40
VAL E  77
GLY E  79
1.79A
None
None
APR  E 201 (-3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E  16
ASP E  14
TYR E 152
LEU E 153
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.29A
None
None
APR  A 201 ( 4.8A)
APR  A 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B  16
ASP B  14
TYR B 152
LEU B 153
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D 155
ASP D  22
TYR D 161
LEU D 164
1.50A
None
APR  D 201 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 151
TYR C 152
THR C  13
LEU C 153
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU E 109
PRO E  98
VAL E 100
ASN E  99
ILE E 106
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C  16
ASP C  14
TYR C 152
LEU C 153
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
ILE C  18
VAL C 155
ILE C  23
1.29A
None
None
APR  C 201 ( 4.9A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO D  98
VAL D 100
ASN D  99
ILE D 106
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
ILE E  18
VAL E 155
ILE E  23
1.29A
None
None
APR  E 201 ( 4.9A)
APR  E 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO E  98
VAL E 100
ASN E  99
ILE E 106
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
ILE D  18
VAL D 155
ILE D  23
1.32A
None
None
None
APR  D 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
VAL E 100
ASN E 101
ILE B 131
PHE B 132
1.55A
None
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 155
ASP C  22
TYR C 161
LEU C 164
1.48A
APR  C 201 ( 4.9A)
APR  C 201 (-3.5A)
EDO  C 203 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.30A
None
None
None
APR  B 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D 151
TYR D 152
THR D  13
LEU D 153
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A 155
ASP A  22
TYR A 161
LEU A 164
1.48A
APR  A 201 ( 4.8A)
APR  A 201 (-3.4A)
EDO  A 203 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL E 155
ASP E  22
TYR E 161
LEU E 164
1.49A
APR  E 201 ( 4.9A)
APR  E 201 (-3.4A)
EDO  E 203 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL D  16
ASP D  14
TYR D 152
LEU D 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C  16
ASP C  14
TYR C 152
LEU C 153
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
ILE B  18
VAL B 155
ILE B  23
1.27A
None
None
EDO  B 202 (-4.0A)
EDO  B 202 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU C 109
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A  16
ASP A  14
TYR A 152
LEU A 153
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO C  98
VAL C 100
ASN C  99
ILE C 106
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU B 109
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.58A
None
None
None
None
EDO  B 204 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 151
TYR C 152
THR C  13
LEU C 153
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
LEU A 109
PRO A  98
VAL A 100
ASN A  99
ILE A 106
1.73A
None
None
None
None
EDO  A 205 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
ILE A  18
VAL A 155
ILE A  23
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL B  16
ASP B  14
TYR B 152
LEU B 153
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
PRO B  98
VAL B 100
ASN B  99
ILE B 106
1.62A
None
None
None
EDO  B 204 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL A 151
TYR A 152
THR A  13
LEU A 153
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
VAL C 155
ASP C  22
TYR C 161
LEU C 164
1.51A
EDO  C 206 ( 4.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
ILE C  18
VAL C 155
ILE C  23
1.28A
None
None
EDO  C 206 ( 4.2A)
EDO  C 206 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 250
PRO A 293
ASN A 203
ALA A 129
ILE A 249
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.38A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 5
PRO B 133
ASN A 447
VAL B 131
ILE B 132
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 221
TYR A 237
THR A 123
LEU A 240
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		4 / 7
PRO D 183
ILE D 172
VAL D 159
ILE D 185
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
LYS A 478
VAL A 475
TYR A 746
LEU A 749
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 7
VAL A  42
ASN A  39
ILE A  37
PHE A  35
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 284
PRO A 232
TYR A 238
LEU A 205
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		4 / 7
PRO B 121
ILE B 107
VAL B 115
ILE B 119
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
ASN A 703
ALA A 706
PHE A 766
VAL A 764
ILE A 757
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A  36
TYR A 788
PRO A 243
LEU A 131
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
NSP8
(SARS-CoV-2)		6 / 12
LEU B 184
ASN A 447
ILE A 450
ALA A 448
VAL B 131
ILE B 185
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 373
ASP A 377
THR A 565
TYR A 530
ILE A 539
1.67A18.72
20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		4 / 7
VAL D 167
ILE D 166
VAL D 159
ILE D 172
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
LYS A 391
VAL B 131
ILE B 185
VAL A 405
GLY A 671
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 5
VAL A 398
ASN B 118
VAL A 675
ILE A 539
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 167
ILE B 185
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 7
ASN A 703
PHE A 766
VAL A 764
ILE A 757
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP8
(SARS-CoV-2)		5 / 12
LEU B 169
VAL B 186
ILE B 132
GLY B 144
ILE B 156
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL B 131
ILE B 185
VAL A 405
ILE A 450
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 576
VAL A 587
ILE A 757
ALA A 762
ILE A 579
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
ASP A 164
TYR A 156
TYR A 175
LEU A 146
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
LYS A 188
THR A 206
TYR A 238
LEU A 241
1.07A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
PRO A 132
ILE A 136
ALA A 173
GLY A 109
ILE A 200
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PRO A 293
VAL A 202
PHE A 230
ILE A 249
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
VAL A 204
PRO A 293
ILE A 259
VAL A 212
ILE A 213
1.33A20.86
20.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
ILE A 259
ALA A 260
VAL A 212
GLY A 215
ILE A 213
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ASP A 358
THR A 538
PRO A 537
TYR A 374
ASN A 657
1.78A18.64
20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_2
(TUBULIN ALPHA CHAIN)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 5
VAL A 398
ASN B 118
VAL A 675
ILE A 539
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PRO B 121
ILE B 107
VAL B 115
ILE B 119
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 576
VAL A 587
ILE A 757
ALA A 762
ILE A 579
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL B 131
ILE B 185
VAL A 405
ILE A 450
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
ASP A 164
TYR A 156
TYR A 175
LEU A 146
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ASN A 703
ALA A 706
PHE A 766
VAL A 764
ILE A 757
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
NSP8
(SARS-CoV-2)		6 / 12
LEU B 184
ASN A 447
ILE A 450
ALA A 448
VAL B 131
ILE B 185
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
VAL A 535
TYR A 346
THR A 538
PRO A 537
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
LYS A 188
THR A 206
TYR A 238
LEU A 241
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
LYS A 391
VAL B 131
ILE B 185
VAL A 405
GLY A 671
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
ASN A 703
PHE A 766
VAL A 764
ILE A 757
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
LYS A 603
VAL A 605
PRO A 809
LEU A 614
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
ASN A 703
PHE A 766
VAL A 764
ILE A 757
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
ILE B 172
VAL B 159
ILE B 185
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv2 NSP8
(SARS-CoV-2)		5 / 12
TYR B 135
THR B 137
ILE B 156
VAL B 159
ILE B 185
1.50A17.75
18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP12
NSP8
(SARS-CoV-2)		6 / 12
LEU B 184
ASN A 447
ILE A 450
ALA A 448
VAL B 131
ILE B 185
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
LYS A 188
THR A 206
TYR A 238
LEU A 241
1.06A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP8
(SARS-CoV-2)		5 / 12
LEU B 169
VAL B 186
ILE B 132
GLY B 144
ILE B 156
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J2T_C_VLBC503_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
LEU A 576
VAL A 587
ILE A 757
ALA A 762
ILE A 579
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
LYS A 603
VAL A 605
PRO A 809
LEU A 614
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PRO B 121
ILE B 107
VAL B 115
ILE B 119
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EB6_C_VLBC503_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 373
ASP A 377
THR A 565
TYR A 530
ILE A 539
1.72A18.64
20.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BMV_C_VLBC507_2
(TUBULIN ALPHA-1B
CHAIN)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL B 131
ILE B 185
VAL A 405
ILE A 450
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1Z2B_C_VLBC800_1
(TUBULIN BETA CHAIN
TUBULIN ALPHA CHAIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
VAL A 373
ASP A 377
THR A 567
TYR A 530
1.52A
None